{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:05:04Z","timestamp":1773932704128,"version":"3.50.1"},"reference-count":10,"publisher":"Pan African Medical Journal","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pan Afr Med J"],"abstract":"<jats:p>Levetiracetam (LEV) is frequently prioritized in epilepsy management due to its minimal drug-drug interactions and perceived metabolic neutrality. However, its potential involvement in severe electrolyte disturbances remains scarcely documented. We describe a 36-year-old male admitted for status epilepticus and initiated on a dose-escalated LEV regimen (2000 mg\/day). The clinical course was complicated by the development of severe, recalcitrant hypokalemia (nadir 2.8 mmol\/L). This electrolyte depletion proved remarkably refractory to intensive parenteral and enteral potassium chloride supplementation. A systematic diagnostic workup successfully excluded extrarenal losses, primary hyperaldosteronism, and renal tubular acidosis. Given the specific temporal alignment with drug intensification, LEV was substituted with phenobarbital. This intervention led to a rapid and sustained restoration of potassium homeostasis within seven days post-withdrawal. Causality was evaluated as highly probable (I5; C2S3). This case, corroborated by recent large-scale epidemiological findings, highlights LEV as a potential trigger for refractory potassium depletion in the adult population. Unlike other antiepileptics, LEV lacks carbonic anhydrase inhibition, suggesting alternative mechanisms such as iatrogenic transcellular shifts or interference with renal ion conductance. We emphasize the necessity of rigorous metabolic monitoring during LEV dose escalation and advocate for an update to official safety labeling to include this metabolic risk, ensuring earlier clinical detection and improved patient safety.<\/jats:p>","DOI":"10.11604\/pamj.2026.53.87.51338","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:36:38Z","timestamp":1773923798000},"source":"Crossref","is-referenced-by-count":0,"title":["Refractory hypokalemia associated with levetiracetam: a case report"],"prefix":"10.11604","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6129-9315","authenticated-orcid":false,"given":"Mohamed","family":"Ksentini","sequence":"first","affiliation":[{"name":"Regional Pharmacovigilance Service in Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rim","family":"Atheymen","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Service in Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lobna Ben","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Service in Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nour El Houda","family":"Ben Ali","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Service in Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Hakim","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Service in Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Zghal","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Service in Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brahim","family":"Kammoun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Habib Bourguiba Hospital of Sfax, University of Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4870","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Coughlin P, Patel G, Vadaketh J, Pandit R. A rare case of levetiracetam-induced refractory hypokalemia. Cureus. 2022;14(4):e23817. PubMed | Google Scholar","DOI":"10.7759\/cureus.23817"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lyseng-Williamson KA. Spotlight on levetiracetam in epilepsy. CNS Drugs. 2011; 25(10):901-5. PubMed | Google Scholar","DOI":"10.2165\/11208340-000000000-00000"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Mbizvo GK, Dixon P, Hutton JL, Marson AG. The adverse effects profile of levetiracetam in epilepsy: a more detailed look. Int J Neurosci. 2014; 124(9):627-34. PubMed | Google Scholar","DOI":"10.3109\/00207454.2013.866951"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Nasrallah K, Silver B. Hyponatremia associated with repeated use of levetiracetam. Epilepsia. 2005; 46(6):972-3. PubMed | Google Scholar","DOI":"10.1111\/j.1528-1167.2005.64004.x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Miremont-Salam\u00e9 G, Th\u00e9ophile H, Haramburu F, B\u00e9gaud B. Causality assessment in pharmacovigilance: The French method and its successive updates. Therapie. 2016; 71(2):179-86. PubMed | Google Scholar","DOI":"10.1016\/j.therap.2016.02.010"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Vallianou NG, Geladari E, Chroni P, Kokkinakis E. Levetiracetam-associated hypokalemia and hypomagnesaemia among two patients treated for seizures. CNS Neurosci Ther. 2015;21(6):539. PubMed | Google Scholar","DOI":"10.1111\/cns.12398"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Contreras-Garc\u00eda IJ, C\u00e1rdenas-Rodr\u00edguez N, Romo-Mancillas A et al. Levetiracetam mechanisms of action: from molecules to systems. Pharmaceuticals (Basel). 2022;15(4):475. PubMed | Google Scholar","DOI":"10.3390\/ph15040475"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Almadani O, Alroba R, Alfakhri A, Almohareb S, Althunian T, Alrwisan AA. Real-world evidence on levetiracetam-induced hypokalemia: an active comparator cohort study. Drugs Real World Outcomes. 2024;11(2):331-9. PubMed | Google Scholar","DOI":"10.1007\/s40801-024-00431-4"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Khateb M, Bosak N, Herskovitz M. The effect of anti-seizure medications on the propagation of epileptic activity: a review. Front Neurol. 2021 May 27:12:674182. PubMed | Google Scholar","DOI":"10.3389\/fneur.2021.674182"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Attilakos A, Dinopoulos A, Paschalidou M, Tsirouda M, Garoufi A. Monitoring of biochemical parameters and coagulation tests in children with epilepsy treated with levetiracetam monotherapy. Childs Nerv Syst. 2019;35(11):2033-4. PubMed | Google Scholar","DOI":"10.1007\/s00381-019-04225-w"}],"container-title":["Pan African Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:36:45Z","timestamp":1773923805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.panafrican-med-journal.com\/content\/article\/53\/87\/full\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":10,"URL":"https:\/\/doi.org\/10.11604\/pamj.2026.53.87.51338","relation":{},"ISSN":["1937-8688"],"issn-type":[{"value":"1937-8688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"51338"}}